If you have been reading about reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-26. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
in the above equation modulo ln(2)) of the parent and daughter, respectively, and BR is the branching ratio. In transient equilibrium, the Bateman equation cannot be simplified by assuming the daughter's half-life is negligible compared to the parent's half-life. The ratio of daughter-to-parent activity is given by:
== Structural studies == As of late 2007, 7 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1VLP, PDB: 1YBE, PDB: 1YIR, PDB: 1YTD, PDB: 1YTE, PDB: 1YTK, and PDB: 2F7F.
== Society and culture == Fibromyalgia causes substantial economic and societal strain due to disability, reduced work hours, informal care, early retirement, and healthcare utilization. According to a 2014 review indirect costs, such as those due to disability and lost productivity, accounted for most of the costs, and the cost to society amounted to "tens of thousands of dollars each year" per patient. A 2022 review of 36 studies found that fibromyalgia causes a significant economic strain on healthcare systems. Annual costs per patient were estimated to be $1,750 to $35,920 in the US, and $1,250 to $8,504 in Europe. People with fibromyalgia can be subjected to significant stigma in society generally, and within the medical system. They may face disbelief in the legitimacy of their pain, moralizing attitudes, and suspicions of malingering, which relate to the invisible nature of the pain and prejudices relating to the historic predominance of women amongst people with the condition. Health professionals may hold negative attitudes towards patients with fibromyalgia, considering them "demanding" or their symptoms to be exaggerated or fake, and they may lack knowledge about the condition, which can also contribute to delays in diagnosis. Many people with fibromyalgia feel that healthcare providers believe they are faking or exaggerating. This stigma can have a considerable impact on the social interactions, trust in healthcare, and mental health of people with fibromyalgia.
In very general terms, the viscous stresses in a fluid are defined as those resulting from the relative velocity of different fluid particles. As such, the viscous stresses must depend on spatial gradients of the flow velocity. If the velocity gradients are small, then to a first approximation the viscous stresses depend only on the first derivatives of the velocity. (For Newtonian fluids, this is also a linear dependence.) In Cartesian coordinates, the general relationship can then be written as
Connor (1961), White House cabinet secretary and staff secretary to President Gerald Ford Brooks Firestone (1961), member of the California State Assembly from the 35th district 1994–1998, founder of Firestone Vineyard and grandson of Harvey S. Firestone Harvey Goldschmid (1962), professor at Columbia Law School, commissioner of the U.S. Securities and Exchange Commission 2002–2005 John A. McMullen (1963), Vermont businessman and Republican Party candidate for the United States Senate representing Vermont in 1998, 2004, and Vermont Attorney General in 2012 Jeff Bell (1965), Republican nominee for United States Senate from New Jersey in 1978, 1982, and in 2014 Mark T. Cox IV (1966), former United States alternate executive director to the World Bank Allan I. Mendelowitz (1966), former chairman and director of the Federal Housing Finance Board Raymond Burghardt (1967), former director, and chairman of the American Institute in Taiwan and U.S. Ambassador to Vietnam Dick Morris (1967), political strategist and advisor to President Bill Clinton and Mexican President Felipe Calderón Mark C. Minton (1967), former U.S. ambassador to Mongolia, and former president of the Korea Society Robert Delahunty (1968), deputy general counsel, White House Office of Homeland Security 2002–2003; professor at University of St. Thomas School of Law Judd Gregg (1969), United States senator from New Hampshire; governor of New Hampshire; U.S. congressman Jerrold Nadler (1969), U.S. congressman from New York Daniel L.
Sources: en.wikipedia.org
== History == In 1889, German physiologist Max Verworn applied a low-level direct current to a mixture of bacterial species and observed that some moved toward the anode and others moved to the cathode. Two years later, in 1891, Belgian microscopist E. Dineur made the first known report of vertebrate cells migrating directionally in a direct current, a phenomenon which he coined galvanotaxis. Dineur used a zinc–copper cell to apply a constant current to the abdominal cavity of a frog via a pair of platinum electrodes. He found that inflammatory leukocytes aggregated at the negative electrode. Since these pioneering studies, a variety of different cell types and organisms have been shown to respond to electric fields.
He appears as the lover of the Lady of the Lake, who bequeaths a powerful sword to Geralt. In the 2023 Warhammer 40,000 novel The Lion: Son of the Forest by Mike Brooks, the protagonist Lion El'Jonson (a character heavily inspired by King Arthur) encounters a wounded king fishing by a lake in a mysterious, alternate dimension. This figure serves as an allegory for the Fisher King, representing the setting's grievously wounded ruler, the Emperor of Mankind.
25 April Downing Street confirms the first UK evacuation flight carrying British citizens has left Sudan. High Court documents reveal that Prince William was paid a "very large sum" by News Group Newspapers, owners of The Sun, to settle historical phone-hacking claims. Data published by the Office for National Statistics indicates government borrowing for the year up to 31 March 2023 to be £139.2bn, less than the £152bn that had been forecast by the Office for Budget Responsibility prior to the 2023 budget. 26 April Andrew Bridgen is expelled from the Conservative Party after comparing COVID-19 vaccines to the Holocaust and being found to have breached lobbying rules. The first evacuation flight from Sudan lands in the UK. The Illegal Migration Bill passes its final stage in the House of Commons, with MPs voting 289–230 in favour of the bill. The UK's Competition and Markets Authority blocks Microsoft's £55bn deal to buy US video game company Activision Blizzard, citing concerns about reduced choice for gamers and reduced innovation; the move needed the approval of competition regulators in the United States, United Kingdom and European Union. 27 April Three days of fresh train strikes are called after both ASLEF and the RMT reject a pay offer from the Rail Delivery Group. The strikes dates are announced for 13 May 31 May and 3 June (ASLEF) and 13 May (RMT).
Not only does the translation from mRNA cause differences, but many proteins also are subjected to a wide variety of chemical modifications after translation. The most common and widely studied post-translational modifications include phosphorylation and glycosylation. Many of these post-translational modifications are critical to the protein's function.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.